Through an exclusive alliance, Endpoint and PRA will now deliver scalable, consistent, and efficient surgical services directly inside client facilities.

For years, preclinical teams have depended on centralized vendors to supply surgically prepared cohorts. While convenient in theory, this model often requires long-distance transport after surgery, introducing variability, delays, and unnecessary costs.

Endpoint Preclinical, together with Preclinical Research Associates (PRA), is changing that. Through an exclusive alliance, we now deliver production-level surgical services directly inside client labs, ensuring faster study readiness, improved outcomes, and reduced reliance on external suppliers.

Read the Press Release.

Instead of on-boarding specialized surgical staff or relying on shipped models, organizations gain a scalable, flexible solution: on-site creation and recovery of models under their own housing and compliance frameworks. This ensures:

• Faster study initiation — models are available without transport or acclimation delays.
• Improved consistency — standardized SOPs and oversight reduce variability, while Endpoint’s managed coordination ensures seamless integration with study workflows.
• Enhanced efficiency — production-scale throughput without adding internal headcount.
• Responsible practices — aligns with the 3Rs, advancing humane standards while improving outcomes.

The PRA team is led by Brad Gien, BSc, CM, a recognized expert with more than 25 years of experience refining complex surgical models in cardiovascular, pharmacokinetic, oncology, and neuroscience programs. Brad’s leadership has helped establish global programs while advancing reproducible, welfare-conscious approaches in translational research. His commitment to mentoring surgical teams and driving consistency at scale sets the foundation for this alliance.

This approach is particularly valuable for organizations running high-throughput programs in cardiovascular, neuroscience, DMPK, infusion toxicology, glucose clamp, and bile duct studies. With Endpoint and PRA, these functions can now be supported directly on-site — eliminating the need for shipped models and enabling alignment with internal SOPs, timelines, and biosecurity standards.

“Partnering with PRA allows us to take a major obstacle out of the research process,” said Cole McLarty, CEO of Endpoint Preclinical. “Instead of managing multiple vendors or waiting on shipped models, study teams can now access surgical expertise right where they work. Our role is to make the process seamless, so scientists can focus on their research while we handle the coordination, logistics, and delivery.”

“At PRA, we know that true consistency begins with responsible practices,” said Brad Gien, President of PRA. “Working with Endpoint means we can bring high-volume surgical programs directly into client facilities, giving research teams immediate access to models they can trust. It’s about saving time, reducing variability, and supporting better science while upholding the highest standards of care.”

This alliance represents more than a partnership — it’s a new standard for how preclinical research can be supported. To explore how on-site production-level services can accelerate your programs, visit our Production-Level Surgery page.

Ready to discuss your needs?